The “anti-pyrimidine effect” of hypoxia and brequinar sodium (NSC 368390) is of consequence for tumor cell growth
- 28 May 1992
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 43 (10) , 2281-2287
- https://doi.org/10.1016/0006-2952(92)90188-o
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- The clinical relevance of tumour hypoxiaEuropean Journal of Cancer and Clinical Oncology, 1990
- Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390)Investigational New Drugs, 1987
- Restimulation of cell cycle progression by hypoxic tumour cells with deoxynucleosides requires ppm oxygen tension*1Experimental Cell Research, 1987
- Anemia: A problem or an opportunity in radiotherapy?International Journal of Radiation Oncology*Biology*Physics, 1986
- RSU 1069, a nitroimidazole containing an aziridine groupBiochemical Pharmacology, 1986
- Deoxycytidylate shortage is a cause of G1 arrest of ascites tumor cells under oxygen deficiencyFEBS Letters, 1983
- Continual presence of oxygen and iron required for mammalian ribonucleotide reduction: Possible regulation mechanismBiochemical and Biophysical Research Communications, 1983
- On the Role of Dihydroorotate Dehydrogenase in Growth Cessation of Ehrlich Ascites Tumor Cells Cultured under Oxygen DeficiencyEuropean Journal of Biochemistry, 1980
- The hypoxic tumor cell: A target for selective cancer chemotherapyBiochemical Pharmacology, 1980
- The cellular location of dihydroorotate dehydrogenase: Relation to de novo biosynthesis of pyrimidinesArchives of Biochemistry and Biophysics, 1976